PDS Biotechnology Corp
F:EU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PDS Biotechnology Corp
F:EU6
|
US |
|
M
|
Mosaic Co
XETRA:02M
|
US |
|
K
|
Kimberly-Clark Corp
SWB:KMY
|
US |
|
Asahi Holdings Inc
TSE:5857
|
JP |
|
A
|
Acen Corp
XPHS:ACEN
|
PH |
PDS Biotechnology Corp
PDS Biotechnology Corp. is a clinical-stage biotech company that develops cancer immunotherapy treatments. Its lead work is based on a drug-delivery and immune-activation platform designed to help the body recognize and attack tumor cells more effectively. The company is not a drug retailer or device maker; it is focused on turning lab research into medicines that can be tested and, if approved, sold to patients. The company’s main customers, if its products reach the market, would be cancer patients through hospitals, oncology clinics, and doctors who prescribe treatment. For now, it makes money mainly through research and development funding, collaboration agreements, and the future sale of approved therapies. Like many biotech firms, its business depends on advancing drug candidates through clinical trials and regulatory review before any product sales begin. What makes PDS Biotechnology different is its role in the biotech value chain: it is building therapies from an internal scientific platform rather than licensing in finished drugs. That means the company’s value comes from proving that its technology can improve immune response against difficult cancers. If successful, it could become a drug developer with proprietary treatments rather than a broad pharmaceutical company.
PDS Biotechnology Corp. is a clinical-stage biotech company that develops cancer immunotherapy treatments. Its lead work is based on a drug-delivery and immune-activation platform designed to help the body recognize and attack tumor cells more effectively. The company is not a drug retailer or device maker; it is focused on turning lab research into medicines that can be tested and, if approved, sold to patients.
The company’s main customers, if its products reach the market, would be cancer patients through hospitals, oncology clinics, and doctors who prescribe treatment. For now, it makes money mainly through research and development funding, collaboration agreements, and the future sale of approved therapies. Like many biotech firms, its business depends on advancing drug candidates through clinical trials and regulatory review before any product sales begin.
What makes PDS Biotechnology different is its role in the biotech value chain: it is building therapies from an internal scientific platform rather than licensing in finished drugs. That means the company’s value comes from proving that its technology can improve immune response against difficult cancers. If successful, it could become a drug developer with proprietary treatments rather than a broad pharmaceutical company.
Trial update: PDS Biotech amended VERSATILE-003 to use progression-free survival as an interim primary endpoint, a change management says could speed an accelerated approval path and reduce trial time and cost.
Enrollment restart: The company said it now has FDA alignment and plans to go back to sites and restart enrollment soon, with sites having stayed engaged during the pause.
Colorectal data: Stage 2 of the colorectal cancer cohort is fully enrolled, and PDS expects additional data on the full population by year-end.
Financials: First-quarter net loss improved to $7.3 million from $8.5 million a year ago, helped by lower operating expenses.
Cash: Cash ended the quarter at $21.7 million, while management said the amended trial design should lower the funding needed to complete the study.
Pipeline: Management highlighted encouraging early data from PDS01ADC in prostate and colorectal cancer and said these results support the broader immuno-oncology pipeline.
IP protection: New U.S. and Japan patents, together with expected biologics exclusivity, were said to extend PDS0101 protection into the 2040s.
